KR20130061148A - 고혈압 치료용 약학 조성물 및 방법 - Google Patents

고혈압 치료용 약학 조성물 및 방법 Download PDF

Info

Publication number
KR20130061148A
KR20130061148A KR1020127031507A KR20127031507A KR20130061148A KR 20130061148 A KR20130061148 A KR 20130061148A KR 1020127031507 A KR1020127031507 A KR 1020127031507A KR 20127031507 A KR20127031507 A KR 20127031507A KR 20130061148 A KR20130061148 A KR 20130061148A
Authority
KR
South Korea
Prior art keywords
dextromethorphan
effective amount
pharmaceutical composition
amlodipine
calcium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127031507A
Other languages
English (en)
Korean (ko)
Inventor
조-웬 첸
시-치에 왕
신-이 주앙
Original Assignee
티에스에이치 바이오팜 코포레이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티에스에이치 바이오팜 코포레이션 리미티드 filed Critical 티에스에이치 바이오팜 코포레이션 리미티드
Publication of KR20130061148A publication Critical patent/KR20130061148A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127031507A 2010-05-03 2011-04-29 고혈압 치료용 약학 조성물 및 방법 Ceased KR20130061148A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03
US61/330,540 2010-05-03
PCT/CN2011/073560 WO2011137734A1 (en) 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension

Publications (1)

Publication Number Publication Date
KR20130061148A true KR20130061148A (ko) 2013-06-10

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127031507A Ceased KR20130061148A (ko) 2010-05-03 2011-04-29 고혈압 치료용 약학 조성물 및 방법

Country Status (11)

Country Link
US (2) US20130053411A1 (enExample)
EP (1) EP2566478A4 (enExample)
JP (1) JP5847162B2 (enExample)
KR (1) KR20130061148A (enExample)
CN (1) CN102869360B (enExample)
AU (1) AU2011250485B2 (enExample)
BR (1) BR112012028153A2 (enExample)
MY (1) MY161853A (enExample)
RU (1) RU2571284C2 (enExample)
TW (1) TWI583383B (enExample)
WO (1) WO2011137734A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126972A1 (en) * 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN107921042A (zh) * 2015-08-20 2018-04-17 东生华制药股份有限公司 包含氨氯地平和右美沙芬的药物组合物
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
DK4101454T3 (da) 2017-01-25 2024-06-17 The George Inst For Global Health Sammensætninger til behandling af hypertension
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
EP0557290A1 (en) * 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
AU2003234621A1 (en) * 2002-05-17 2003-12-02 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
WO2006033965A2 (en) 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
BRPI0819883A2 (pt) * 2007-11-28 2017-05-23 Sequoia Pharmaceuticals Inc composições e métodos para inibir citocromo p450 2d6

Also Published As

Publication number Publication date
TWI583383B (zh) 2017-05-21
RU2012151051A (ru) 2014-06-10
AU2011250485B2 (en) 2016-07-07
EP2566478A1 (en) 2013-03-13
TW201206437A (en) 2012-02-16
EP2566478A4 (en) 2014-04-30
MY161853A (en) 2017-05-15
AU2011250485A1 (en) 2012-12-06
BR112012028153A2 (pt) 2018-08-07
CN102869360A (zh) 2013-01-09
JP5847162B2 (ja) 2016-01-20
WO2011137734A1 (en) 2011-11-10
RU2571284C2 (ru) 2015-12-20
JP2013525460A (ja) 2013-06-20
US9744165B2 (en) 2017-08-29
US20160235741A1 (en) 2016-08-18
US20130053411A1 (en) 2013-02-28
CN102869360B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
US9744165B2 (en) Method for treating hypertension
HUT77315A (hu) Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra
KR20090087009A (ko) 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
JP2005532330A (ja) Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ
WO2019241020A1 (en) Serdexmethylphenidate conjugates, compositions and methods of use thereof
WO2003057205A2 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
BRPI0807829A2 (pt) " inibidores de epóxido hidrolase solúvel para o tratamento de síndrome metabólica e desordens relacionadas ".
EP1715863B1 (en) Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
ES2847904T3 (es) Medicamento para la prevención o el tratamiento de la hipertensión
Guarneri et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
EP2118048B1 (en) Male contraceptive
JPS63310867A (ja) 抗鬱病剤作用を有する新規な結合生成物
CN105924382B (zh) S-马尼地平盐酸盐i晶型及其制备方法
US8604054B2 (en) Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
KR20050016452A (ko) Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물
TW201304775A (zh) 使用依普羅沙坦與氨氯地平治療高血壓的組成物和方法
ITRM20100230A1 (it) Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP0965341A2 (en) Combination of dofetilide and a calcium channel blocker
NZ542640A (en) Use of angiontensin II antagonists including losartan, candesartan, cilexetil, irbesartan and candesartan for the treatment or prevention of metabolic syndrome or Syndrome X
MXPA99004460A (en) Combination of dofetilida and a blocking of the calculates
HK1128233A (en) COMBINATION OF TRIAZINE DERIVATIVES AND PPARα AGONISTS

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160404

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161214

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I